A fireside conversation for biopharma, investors, and academics about maximizing translational insights from proteomic data by capitalizing on the emergence of large-scale technologies including mass spec and genetics data.

Abstract:

Despite decades of clinical trial investment, fewer than 10% of drugs reach approval. This failure rate is driven, in part, by an inadequate understanding of the causal biology underlying disease. Targeted proteomics platforms have been fundamental in understanding causal biology. However, limitations in their inability to resolve isoforms, post-translational modifications, and susceptibility to false pQTLs from epitope artifacts limit discovery potential.

This topic of discussion brings together Gary J. Patti (Panome Bio / Washington University) and Dipender Gill (Sequoia Genetics  ...